We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 25, 2022

Assessing cfDNA Concentrations in the Perioperative Period Can Predict Recurrence Risk in Patients With Non-Metastatic Breast Cancer

Surgical Oncology


Additional Info

Surgical Oncology
Assessment of cell-free DNA (cfDNA) concentrations in the perioperative period can predict risk of recurrence in patients with non-metastatic breast cancer
Surg Oncol 2022 Jun 01;42(2022)101753, F Hassan, JH Wang, C Cullinane, M Ita, M Corrigan, DP O'Leary, HP Redmond

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading